ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

enzalutamide

Also written as “Enzalutamide”, “MDV3100” and “HC-1119”.

Its studies are mostly in Prostatic Neoplasms · Neoplasms · Breast Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasm Metastasis, led by 6 companies.

Drug pageEnzalutamide: every studyMany companies study it; this page follows only the 54 they lead. All 176 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 31, 201354 company-led studies, 7 open or runningNext primary completion: Apr 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma313 open or runningphase 4since Oct 31, 2013Jan 18, 2011Apr 30, 2027phase 1 · NCT07783282
Pfizerits history only162 open or runningphase 4since Nov 18, 2013Jul 31, 2007none ahead
Hinova Pharmaceuticalsits history only41 open or runningphase 3since Feb 17, 2019Dec 11, 2018none ahead
Alessa Therapeuticsits history only11 open or runningphase 1since Dec 14, 2023Dec 14, 2023Dec 30, 2028phase 1 · NCT06257693
Applied Biologyits history only10 open or runningphase 3since Jul 28, 2021Jul 28, 2021none ahead
Hinova Pharmaceuticals USAits history only10 open or runningphase 3since Feb 20, 2019Feb 20, 2019none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Medivation LLC, a wholly owned subsidiary of Pfizer and Gilead Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 15 studies since Jan 18, 2011.

  1. Apr 25, 2014Phase 2 study in Prostatic NeoplasmsNCT02124668 · 30 enrolled · Georgia, Russian Federation
  2. May 12, 20142 phase 1 studiesNCT02138162, NCT02138799
  3. Aug 22, 2014Phase 1 study in Prostatic NeoplasmsNCT02225093 · 12 enrolled · Moldova, Republic of
  4. Nov 7, 20142 phase 3 studiesNCT02288247, NCT02294461
  5. May 8, 2015Phase 4 study in Neoplasm MetastasisNCT02441517 · 4 enrolled · United States
  6. Aug 18, 2015Phase 2 study in Advanced Hepatocellular CarcinomaNCT02528643 · 165 enrolled · United States, Canada, Hong Kong and more
  7. Feb 5, 2016Phase 3 study in Metastatic Hormone Sensitive Prostate CancerNCT02677896 · 1,150 enrolled · United States, Argentina, Australia and more
  8. Feb 29, 2016Phase 2 study in Prostatic NeoplasmsNCT02799745 · 227 enrolled · United States, Canada
  9. Sep 27, 2016Phase 4 study in Prostatic NeoplasmsNCT02918968 · 206 enrolled · Japan
  10. Nov 7, 2016Phase 2 study in Prostatic NeoplasmsNCT02960022 · 900 enrolled · United States, Argentina, Australia and more
  11. Aug 20, 2018Phase 4 study in Metastatic Castration Resistant Prostate CancerNCT03641560 · 52 enrolled · India
  12. Aug 19, 2019Phase 3 study in Metastatic Hormone Sensitive Prostate CancerNCT04076059 · 180 enrolled · China
  13. Sep 17, 2019Phase 1 study in Prostatic NeoplasmsNCT04094519 · 24 enrolled · Moldova, Republic of
  14. Aug 20, 2026Phase 1 study in Prostatic NeoplasmsNCT07783282 · 56 planned · Bulgaria

Ahead

  1. Apr 30, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07783282
  2. Jul 31, 2029Primary completion: phase 2 study in Prostatic NeoplasmsNCT02960022

TargetBeta

AR →read by rule
“A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 31 Astellas Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07783282Prostatic Neoplasms · Bulgaria1RecruitingApr 30, 202756
NCT04094519Prostatic Neoplasms · Moldova, Republic of1CompletedDec 27, 202024
NCT04076059Metastatic Hormone Sensitive Prostate Cancer · China3Active, not recruitingNov 18, 2022180
NCT03641560Metastatic Castration Resistant Prostate Cancer · India4CompletedFeb 20, 202452
NCT02960022Prostatic Neoplasms · United States, Argentina, Australia and more2Active, not recruitingJul 31, 2029900
NCT02918968Prostatic Neoplasms · Japan4CompletedMar 27, 2020206
NCT02799745Prostatic Neoplasms · United States, Canada2CompletedAug 28, 2020227
NCT02677896Metastatic Hormone Sensitive Prostate Cancer · United States, Argentina, Australia and more3CompletedOct 14, 20181,150
NCT02528643Advanced Hepatocellular Carcinoma · United States, Canada, Hong Kong and more2CompletedOct 2, 2017165
NCT02441517Neoplasm Metastasis · United States4TerminatedMar 15, 20174
NCT02294461Bulbo-Spinal Atrophy, X-Linked · China, Hong Kong, South Korea and more3CompletedSep 20, 2015395
NCT02288247Neoplasm Metastasis · Austria, Belgium, Czechia and more3CompletedApr 30, 2020688
NCT02225093Prostatic Neoplasms · Moldova, Republic of1CompletedFeb 3, 201412
NCT02138799Drug-Drug Interaction (DDI) · Germany1CompletedSep 201328
NCT02138162Severe Hepatic Impairment · Bulgaria1CompletedMar 201416
NCT02124668Prostatic Neoplasms · Georgia, Russian Federation2CompletedMay 25, 201730
NCT02116582Metastatic Castration-Resistant Prostate Cancer · Belgium, France, Germany and more4CompletedMay 8, 2016215
NCT02091960Breast Neoplasms · United States, Belgium, Canada and more2CompletedFeb 28, 2017103
NCT01977651Seizures · United States, Argentina, Australia and more4CompletedFeb 1, 2016424
NCT01913379Healthy Subjects · France1CompletedDec 201141
NCT01911741Healthy Subjects · Germany1CompletedMar 201355
NCT01911728Pharmacokinetics of MDV3100 · South Africa1CompletedFeb 21, 201214
NCT01911715Healthy Subjects · Netherlands1CompletedJul 20116
NCT01902251Prostatic Neoplasms · United States1CompletedOct 201327
NCT01901133Kidney Diseases · Moldova, Republic of1CompletedJan 201233
NCT01663415Neoplasms2WithdrawnOct 20140
NCT01650194Neoplasms · United States2CompletedJan 4, 201860
NCT01534052Prostatic Neoplasms · United States, Moldova, Republic of, South Africa2CompletedApr 18, 201752
NCT01302041Prostatic Neoplasms · Belgium, Czechia, Denmark and more2CompletedJul 29, 201267
NCT01288911Prostatic Neoplasms · United States, Belgium, Canada and more2CompletedOct 19, 2014375
NCT01284920Prostatic Neoplasms · Japan2CompletedJul 12, 201247

How it is read

Names in the registry

  • “Enzalutamide”, 40 entries
  • “enzalutamide”, 13 entries
  • “MDV3100”, 8 entries
  • “HC-1119”, 4 entries
  • “HC1119”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.